Wednesday, 22 February 2017

Dr Reddy`s Miryalaguda facility gets 3 USFDA observations

Dr Reddy's Laboratories said the US health regulator has made three observations after completing inspection of its Miryalaguda facility. "The audit of the company's Active Pharmaceutical Ingredients (API) manufacturing plant at Miryalaguda, by the United States Food and Drug Administration (USFDA), has been completed on February 21, 2017," Dr Reddy's Laboratories said in a filing to BSE.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.